Skip to main navigation Skip to search Skip to main content

Developing antineoplastic agents that target peroxisomal enzymes: Cytisine-linked isoflavonoids as inhibitors of hydroxysteroid 17-beta-dehydrogenase-4 (HSD17B4)

  • Mykhaylo S. Frasinyuk
  • , Wen Zhang
  • , Przemyslaw Wyrebek
  • , Tianxin Yu
  • , Xuehe Xu
  • , Vitaliy M. Sviripa
  • , Svitlana P. Bondarenko
  • , Yanqi Xie
  • , Huy X. Ngo
  • , Andrew J. Morris
  • , James L. Mohler
  • , Michael V. Fiandalo
  • , David S. Watt
  • , Chunming Liu
  • University of Kentucky
  • NASU - Institute of Bioorganic Chemistry and Petrochemistry
  • National University of Food Technologies
  • Roswell Park Cancer Institute

Research output: Contribution to journalArticlepeer-review

26 Scopus citations

Abstract

Cytisine-linked isoflavonoids (CLIFs) inhibited PC-3 prostate and LS174T colon cancer cell proliferation by inhibiting a peroxisomal bifunctional enzyme. A pull-down assay using a biologically active, biotin-modified CLIF identified the target of these agents as the bifunctional peroxisomal enzyme, hydroxysteroid 17β-dehydrogenase-4 (HSD17B4). Additional studies with truncated versions of HSD17B4 established that CLIFs specifically bind the C-terminus of HSD17B4 and selectively inhibited the enoyl CoA hydratase but not the d-3-hydroxyacyl CoA dehydrogenase activity. HSD17B4 was overexpressed in prostate and colon cancer tissues, knocking down HSD17B4 inhibited cancer cell proliferation, suggesting that HSD17B4 is a potential biomarker and drug target and that CLIFs are potential probes or therapeutic agents for these cancers.

Original languageEnglish
Pages (from-to)7623-7629
Number of pages7
JournalOrganic and Biomolecular Chemistry
Volume15
Issue number36
DOIs
StatePublished - 2017

Fingerprint

Dive into the research topics of 'Developing antineoplastic agents that target peroxisomal enzymes: Cytisine-linked isoflavonoids as inhibitors of hydroxysteroid 17-beta-dehydrogenase-4 (HSD17B4)'. Together they form a unique fingerprint.

Cite this